Management Team

Fahar Merchant, PhD

President and Chief Executive Officer

Dr. Merchant is a biotech veteran with 30 years of experience as a serial entrepreneur and co-founder of Medicenna. Previously he was President and CEO of Protox Therapeutics Inc. where he transitioned a pre-clinical start-up to a Phase 3 ready uro-oncology company in six years (2005-2011). In 1992, he co-founded IntelliGene Expressions, Inc., a biologics cGMP compliant CDMO, and built it to one of the fastest-growing companies in Canada ensuring profitability during his tenure as CEO. In 2000, by strategic in-licensing, he co-founded Avicenna Medica, Inc., a clinical stage oncology company, and sold it a year later to KS Biomedix (LSE) for $90 million. Fahar was CTO and Director of KS Biomedix until its acquisition by Xenova (NASDAQ and LSE) in 2003. He has raised over $150 million from public and private sources to fund the development of targeted therapies for oncology and closed corporate transactions valued at over $250 million. Fahar holds a BSc in Biochemistry and Pharmacology from Aston University, MSc in Biotechnology from Birmingham University, and a Ph.D. in Biochemical Engineering from Western University.

Humphrey Gardner, MD

Chief Medical Officer

Dr. Gardner’s career in the biopharmaceutical industry spans over two decades. Most recently Dr. Gardner served as CMO at Harbour BioMed advancing novel antibody and bispecific therapeutics in oncology. Previously, he was the CMO at Stingthera, CMO in Residence at Roivant Sciences and Chief of Medical Oncology at Evelo Biosciences, a Flagship Pioneering company. Prior to this, Dr. Gardner held senior roles at AstraZeneca as Clinical Vice President Translational Medicine, Oncology, at Novartis as Executive Director, Oncology Translational Laboratories and at Biogen. Previously, in academia, Dr. Gardner was Assistant Professor at The Scripps Research Institute, Research Fellow at the Whitehead Institute, MIT, Clinical fellow at Harvard Medical School and completed his internship at the Memorial University of Newfoundland. Dr. Gardner is a Fellow of the College of American Pathologists and has authored nearly 100 publications. Dr. Gardner holds a bachelor’s degree in Biochemistry and his medical degree from the University of Cambridge.

Rosemina Merchant, MESc

Chief Development Officer

Ms. Merchant has over 30 years of experience in the development of biopharmaceuticals. Prior to co-founding Medicenna, Ms. Merchant was Senior VP of Development and Regulatory Affairs at Protox Therapeutics, Inc (TSX), and responsible for the development of PRX302 (Topsalysin) a PSA activated protoxin for localized prostate cancer and BPH. She transitioned PRX302, a discovery project to Phase 3 readiness in 6 years. During that time, she executed multiple clinical trials, managed Canadian and the United States regulatory filings, and led all CMC related outsourcing activities in the United States and Europe. In 1992, Nina co-founded, IntelliGene Expressions, Inc., a biologics cGMP compliant CDMO, where she was VP of Manufacturing and Chief Operating Officer. Nina also held a variety of senior-level positions at KS Biomedix, GE LifeSciences, Alberta Innovates, Bioniche, and Sanofi Pasteur. She holds a B.Sc in Pharmacology and Chemistry from Aston University, MSc in Applied Organic Chemistry from Birmingham University, and M.E.Sc. in Biochemical Engineering from Western University.